Tyrosinase Expression and Melanoma Prognosis
Author Information
Author(s): Osella-Abate S, Savoia P, Quaglino P, Fierro M T, Leporati C, Ortoncelli M, Bernengo M G
Primary Institution: University of Turin
Hypothesis
Is tyrosinase mRNA expression in the peripheral blood of stage III melanoma patients associated with disease progression?
Conclusion
Tyrosinase expression in the blood is linked to a higher risk of melanoma relapse and shorter disease-free survival.
Supporting Evidence
- 49% of patients showed at least one positive tyrosinase result during follow-up.
- 72.9% of patients with positive tyrosinase results relapsed.
- Median disease-free survival was significantly lower in tyrosinase-positive patients.
Takeaway
This study found that checking for a specific marker in the blood can help doctors know if melanoma might come back after treatment.
Methodology
RT–PCR was used to evaluate tyrosinase mRNA expression in blood samples from melanoma patients during follow-up.
Potential Biases
Potential bias in patient selection and treatment variations.
Limitations
The study may not account for all variables influencing disease progression.
Participant Demographics
110 stage III melanoma patients, 55 male and 55 female, aged 24 to 82 years.
Statistical Information
P-Value
0.0098
Confidence Interval
95% CI 63.3–83.3%
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website